Posted by Michael Wonder on 26 Jul 2025
Pfizer and BioNTech receive positive CHMP opinion for LP.8.1 adapted COVID-19 vaccine in the European Union
25 July 2025 - Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sub-lineages – including the XFG and NB.1.8.1 variants – compared to 2024-2025 COVID-19 vaccine formulations.
Pfizer and BioNTech announced today that the EMA's CHMP has recommended marketing authorisation for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (Comirnary LP.8.1) for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
